Sign in

    Matt Biegler

    Research Analyst at Oppenheimer & Co. Inc.

    Matt Biegler's questions to Marker Therapeutics (MRKR) leadership

    Matt Biegler's questions to Marker Therapeutics (MRKR) leadership • Q1 2020

    Question

    Matt Biegler from Oppenheimer & Co. Inc. inquired about the patient enrollment sequence for the Phase 2 AML trial, specifically asking if the first three patients using the legacy reagent must be treated before enrolling patients with the new MT-401 reagent. He also asked for details on the upcoming pancreatic cancer trial update at ASCO.

    Answer

    Chief Medical Officer Dr. Mythili Koneru clarified that patients from both reagent groups can be enrolled simultaneously, provided there is a two-week interval between each patient's first treatment. She confirmed that the ability to enroll patients with the new reagent depends on the manufacturer providing the certificate of analysis, not on the completion of the first cohort. President and CEO Peter Hoang noted that more details on the pancreatic cancer trial would be available after the ASCO abstracts are released.

    Ask Fintool Equity Research AI

    Matt Biegler's questions to Marker Therapeutics (MRKR) leadership • Q3 2019

    Question

    Matt Biegler from Oppenheimer & Company asked about the potential worst-case scenario for the IND delay, the AML trial design, and the timing of new data from Baylor.

    Answer

    SVP of Clinical Development, Dr. Mythili Koneru, expressed confidence in initiating the Phase 2 trial in 2020, stating they have worked closely with the reagent manufacturers. She confirmed the trial design remains unchanged, targeting both adjuvant and active disease settings. Dr. Koneru also noted that updated data from the Baylor studies is expected next year and that higher-dose testing in the AML study has already commenced.

    Ask Fintool Equity Research AI